Fill in your contactinformation to download the whitepaper

Whitepaper consent
Newsletter consent

Fuel for bold innovators

Enabling the future of Healthcare and Life Sciences 

Creating the next generation of HealthTech ventures 

HERAN is enabling the next generation of healthcare and life sciences technology breakthroughs. 

As an active and engaged investor, we invest in great science, bold innovators and companies that aim to have transformative impact.

 

“Wind extinguishes a candle and energizes a fire”

We invest in teams that are tough, intelligent, perseverant and possess high levels of genuine positivity and an incredible drive to move things forward.

Discover our portfolio

With our expertise, network, guidance, and strong focus we aim to support those pioneers, disruptors and entrepreneurs who want and can improve healthcare in all its facets. We focus on innovation, technologies and science that can generate scalable positive impact and disruption within Life Sciences and healthcare. 

 logo
Invested:
2025
Country:
BE

Gynaia is a women’s health diagnostics company that empowers gynecological professionals with continuous learning, certification, and clinical-grade AI tools to improve care in gynecologic oncology, early pregnancy, obstetrics, fertility, and beyond. 
By combining explainable AI, regulatory-grade software, and a global expert network, Gynaia enables faster triage, earlier diagnoses, and fewer unnecessary procedures.

 logo
Invested:
2025
Country:
BE

Nuclivision develops software solutions for nuclear imaging, enhancing efficiency across the entire clinical workflow. Its mission is to support patients by improving the quality, safety, and accessibility of nuclear medicine. Their first product Nuclarity enables nuclear medicine physicians to perform PET scans with up to 50% less radioactivity and scan time

 logo
Invested:
2023
Country:
BE

ImmuneSpec has developed a proprietary approach & process to conduct highly sensitive MAPPS assays, i.e., the analysis of MHC-associated peptide proteomics. This immunogenicity testing indicates whether a protein drug will result in a potential activation of the immune system. 

Who are we?

Heran Partners is a specialist venture capital investor committed to creating transformative impact within the life sciences and healthcare industry. We are a Belgium-based investment fund driven by a dedicated team with strong scientific and entrepreneurial backgrounds. We provide venture & growth capital accompanied by a strong network, expertise and mentorship to start-ups and scale-ups with a solid technology platform and strong market potential. 

News & insights

Gynaia raises € 2.3 million in seed round co-led by Heran Partners and Gemma Frisius Fund

Brecht Claerhout

ONTOFORCE appoints Brecht Claerhout as new Chief Executive Officer

Brecht brings over two decades of experience in the life sciences industry, with a strong background in data integration and innovation.

Read on

Curious about what we
can do for you?

We’d love to hear your pitch!